Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy

Trial Profile

Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Jul 2014

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 10 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top